May 18 (Reuters) - Avita Medical Ltd AVH.AX
* Company on-track to file a PMA with U.S. Food & Drug Administration in mid-2017
* Co-primary endpoints achieved in trial deploying recell in patients with severe burns Source text for Eikon: ID:nASX8brB5v Further company coverage: AVH.AX